Home   About this service   Get the news  
+32 2 743 34 03

 Belgium  Other Countries
Page : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - ...
UCB [BE0003739530/UCB]   
[13/03/2019]

UCB : UCB Media Room: Transparency Notification

Transparency notification UCB SA/NVNotification referring to situation on 8 March 2019Threshold crossed: 3%Latest holding: 3.07%Brussels Belgium, 13 March 2019 – 20:00 CET – regulated information1. Summary of the notificationPursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has filed a transparency notification.The... See more
 
UCB [BE0003739530/UCB]   
[02/03/2019]

UCB : UCB Media Room: AAD bimekizumab

Bimekizumab Demonstrated LongTerm Maintenance of Complete or Almost Complete Skin Disease Resolution for Psoriasis Patients in BE ABLE 2 Extension Study80 to 100% of BE ABLE 1 responders maintained a response of at least 90% disease improvement PASI90 over 60 weeks with bimekizumabThese positive results mark the longestterm data to date demonstrating durable PASI90/PASI100 outcomes to 60 weeks... See more
 
UCB [BE0003739530/UCB]   
[01/03/2019]

UCB : UCB Media Room: AAD 2019 Curtain Raiser

New Data Affirms Strength of UCB ImmunoDermatology PortfolioLate breaking presentation of the Phase 2b longterm findings on the investigational molecule, bimekizumab, demonstrates complete or almost complete skin clearance in moderatetosevere plaque psoriasisLongterm data from Phase 3 studies CIMPASI1, CIMPASI2 and CIMPACT highlight the strong efficacy and durability of CIMZIA® certolizumab... See more
 
UCB [BE0003739530/UCB]   
[28/02/2019]

UCB : UCB Media Room

UCB Full Year Report 2018:2018 marks the fifth consecutive year of profitable growth, intensifying investment in UCB’s strong pipelineBrussels Belgium, 28 February 2019 – 7:00 CET – regulated information –Revenue reached € 4.6 billion: 2%, 5% CER1; net sales increased to € 4.4 billion: 5%, 8% CER, driven by core products 6%, 10% CERUnderlying profitability rEBITDA increased to € 1... See more
 
UCB [BE0003739530/UCB]   
[15/02/2019]

UCB : UCB Media Room: Kings College London

UCB builds on its R&D footprint to form a research satellite facility within King’s College LondonUCB builds on its strategy of enhancing capabilities by establishing satellite research facilities in innovative environments, embedding company scientists within global centres of excellence to complement its two major international research hubs in Belgium and the UKThe collaboration with... See more